BIOLASE INC (BIOL) Fundamental Analysis & Valuation

NASDAQ:BIOL • US0909117022

Current stock price

0.129 USD
-0.02 (-13.19%)
At close:
0.109 USD
-0.02 (-15.5%)
After Hours:

This BIOL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BIOL Profitability Analysis

1.1 Basic Checks

  • In the past year BIOL has reported negative net income.
  • In the past year BIOL has reported a negative cash flow from operations.
  • In the past 5 years BIOL always reported negative net income.
  • BIOL had a negative operating cash flow in each of the past 5 years.
BIOL Yearly Net Income VS EBIT VS OCF VS FCFBIOL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • BIOL has a Return On Assets of -111.37%. This is amonst the worse of the industry: BIOL underperforms 84.04% of its industry peers.
  • Looking at the Return On Equity, with a value of -14222.30%, BIOL is doing worse than 91.49% of the companies in the same industry.
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROIC N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
BIOL Yearly ROA, ROE, ROICBIOL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

  • BIOL's Gross Margin of 34.26% is on the low side compared to the rest of the industry. BIOL is outperformed by 69.68% of its industry peers.
  • BIOL's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BIOL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
BIOL Yearly Profit, Operating, Gross MarginsBIOL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. BIOL Health Analysis

2.1 Basic Checks

  • BIOL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BIOL has more shares outstanding than it did 1 year ago.
  • BIOL has a worse debt/assets ratio than last year.
BIOL Yearly Shares OutstandingBIOL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
BIOL Yearly Total Debt VS Total AssetsBIOL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -13.20, we must say that BIOL is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -13.20, BIOL is doing worse than 83.51% of the companies in the same industry.
  • BIOL has a Debt/Equity ratio of 41.66. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of BIOL (41.66) is worse than 91.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Altman-Z -13.2
ROIC/WACCN/A
WACC12.07%
BIOL Yearly LT Debt VS Equity VS FCFBIOL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • BIOL has a Current Ratio of 1.17. This is a normal value and indicates that BIOL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.17, BIOL is not doing good in the industry: 89.89% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.64 indicates that BIOL may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.64, BIOL is not doing good in the industry: 95.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.64
BIOL Yearly Current Assets VS Current LiabilitesBIOL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIOL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 95.89% over the past year.
  • BIOL shows a small growth in Revenue. In the last year, the Revenue has grown by 0.13%.
  • The Revenue has been growing slightly by 1.27% on average over the past years.
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%

3.2 Future

  • Based on estimates for the next years, BIOL will show a very strong growth in Earnings Per Share. The EPS will grow by 41.31% on average per year.
  • BIOL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.36% yearly.
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIOL Yearly Revenue VS EstimatesBIOL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
BIOL Yearly EPS VS EstimatesBIOL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BIOL Valuation Analysis

4.1 Price/Earnings Ratio

  • BIOL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOL Price Earnings VS Forward Price EarningsBIOL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOL Per share dataBIOL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • BIOL's earnings are expected to grow with 41.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.31%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIOL Dividend Analysis

5.1 Amount

  • No dividends for BIOL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOL Fundamentals: All Metrics, Ratios and Statistics

BIOLASE INC

NASDAQ:BIOL (6/18/2024, 8:15:46 PM)

After market: 0.109 -0.02 (-15.5%)

0.129

-0.02 (-13.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13
Earnings (Next)08-08
Inst Owners0%
Inst Owner Change0%
Ins Owners37.15%
Ins Owner Change0%
Market Cap4.31M
Revenue(TTM)48.83M
Net Income(TTM)-38.26M
Analysts80
Price Target1.99 (1442.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.57%
Min EPS beat(2)-107.61%
Max EPS beat(2)32.47%
EPS beat(4)1
Avg EPS beat(4)-58.19%
Min EPS beat(4)-107.61%
Max EPS beat(4)32.47%
EPS beat(8)2
Avg EPS beat(8)-48.85%
EPS beat(12)4
Avg EPS beat(12)-28.48%
EPS beat(16)6
Avg EPS beat(16)-25.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.51%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-8.78%
Min Revenue beat(4)-23.29%
Max Revenue beat(4)-0.64%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)7
Avg Revenue beat(12)1.12%
Revenue beat(16)10
Avg Revenue beat(16)3.28%
PT rev (1m)-82.63%
PT rev (3m)-86.55%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)84.04%
EPS NY rev (1m)-37.5%
EPS NY rev (3m)76.15%
Revenue NQ rev (1m)-4.26%
Revenue NQ rev (3m)-8.58%
Revenue NY rev (1m)-1.61%
Revenue NY rev (3m)-4.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 16.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.25
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.46
BVpS0.01
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.26%
FCFM N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
F-Score3
Asset Turnover1.42
Health
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.8%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.64
Altman-Z -13.2
F-Score3
WACC12.07%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)202.36%
Cap/Sales(3y)4.06%
Cap/Sales(5y)2.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.89%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.18%
OCF growth 3YN/A
OCF growth 5YN/A

BIOLASE INC / BIOL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOLASE INC?

ChartMill assigns a fundamental rating of 1 / 10 to BIOL.


What is the valuation status of BIOLASE INC (BIOL) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOLASE INC (BIOL). This can be considered as Overvalued.


What is the profitability of BIOL stock?

BIOLASE INC (BIOL) has a profitability rating of 0 / 10.


What is the earnings growth outlook for BIOLASE INC?

The Earnings per Share (EPS) of BIOLASE INC (BIOL) is expected to grow by 98.59% in the next year.